These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 7738660

  • 1. Pharmacokinetics of chimeric L6 conjugated to indium-111- and yttrium-90-DOTA-peptide in tumor-bearing mice.
    DeNardo SJ, Zhong GR, Salako Q, Li M, DeNardo GL, Meares CF.
    J Nucl Med; 1995 May; 36(5):829-36. PubMed ID: 7738660
    [Abstract] [Full Text] [Related]

  • 2. Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer.
    Denardo SJ, Richman CM, Goldstein DS, Shen S, Salako Q, Kukis DL, Meares CF, Yuan A, Welborn JL, Denardo GL.
    Anticancer Res; 1997 May; 17(3B):1735-44. PubMed ID: 9179227
    [Abstract] [Full Text] [Related]

  • 3. Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts.
    DeNardo GL, Kroger LA, Meares CF, Richman CM, Salako Q, Shen S, Lamborn KR, Peterson JJ, Miers LA, Zhong GR, DeNardo SJ.
    Clin Cancer Res; 1998 Oct; 4(10):2483-90. PubMed ID: 9796981
    [Abstract] [Full Text] [Related]

  • 4. Biodistribution of 111In- and 90Y-labeled DOTA and maleimidocysteineamido-DOTA conjugated to chimeric anticarcinoembryonic antigen antibody in xenograft-bearing nude mice: comparison of stable and chemically labile linker systems.
    Williams LE, Lewis MR, Bebb GG, Clarke KG, Odom-Maryon TL, Shively JE, Raubitschek AA.
    Bioconjug Chem; 1998 Oct; 9(1):87-93. PubMed ID: 9460550
    [Abstract] [Full Text] [Related]

  • 5. Yttrium-90-DOTA-peptide-chimeric L6 radioimmunoconjugate: efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts.
    DeNardo SJ, Kukis DL, Miers LA, Winthrop MD, Kroger LA, Salako Q, Shen S, Lamborn KR, Gumerlock PH, Meares CF, DeNardo GL.
    J Nucl Med; 1998 May; 39(5):842-9. PubMed ID: 9591587
    [Abstract] [Full Text] [Related]

  • 6. Development of tumor targeting bioprobes ((111)In-chimeric L6 monoclonal antibody nanoparticles) for alternating magnetic field cancer therapy.
    DeNardo SJ, DeNardo GL, Miers LA, Natarajan A, Foreman AR, Gruettner C, Adamson GN, Ivkov R.
    Clin Cancer Res; 2005 Oct 01; 11(19 Pt 2):7087s-7092s. PubMed ID: 16203807
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and toxicity of radioimmunotherapy with (90)Y-DOTA-peptide-ChL6 for PC3-tumored mice.
    O'Donnell RT, DeNardo SJ, DeNardo GL, Miers L, Lamborn KR, Kukis DL, Meyers FJ.
    Prostate; 2000 Aug 01; 44(3):187-92. PubMed ID: 10906734
    [Abstract] [Full Text] [Related]

  • 8. Labeling monoclonal antibodies with 90yttrium- and 111indium-DOTA chelates: a simple and efficient method.
    Li M, Meares CF, Zhong GR, Miers L, Xiong CY, DeNardo SJ.
    Bioconjug Chem; 1994 Aug 01; 5(2):101-4. PubMed ID: 8031871
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics of pretargeted monoclonal antibody 2D12.5 and 88Y-Janus-2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA) in BALB/c mice with KHJJ mouse adenocarcinoma: a model for 90Y radioimmunotherapy.
    Goodwin DA, Meares CF, Watanabe N, McTigue M, Chaovapong W, Ransone CM, Renn O, Greiner DP, Kukis DL, Kronenberger SI.
    Cancer Res; 1994 Nov 15; 54(22):5937-46. PubMed ID: 7954426
    [Abstract] [Full Text] [Related]

  • 10. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
    Griffiths GL, Govindan SV, Sharkey RM, Fisher DR, Goldenberg DM.
    J Nucl Med; 2003 Jan 15; 44(1):77-84. PubMed ID: 12515879
    [Abstract] [Full Text] [Related]

  • 11. Biodistribution and dosimetry of pretargeted monoclonal antibody 2D12.5 and Y-Janus-DOTA in BALB/c mice with KHJJ mouse adenocarcinoma.
    Lubic SP, Goodwin DA, Meares CF, Song C, Osen M, Hays M.
    J Nucl Med; 2001 Apr 15; 42(4):670-8. PubMed ID: 11337558
    [Abstract] [Full Text] [Related]

  • 12. Prelabeling of chimeric monoclonal antibody L6 with 90yttrium- and 111indium-1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA) chelates for radioimmunodiagnosis and therapy.
    Li M, Meares CF, Salako Q, Kukis DL, Zhong GR, Miers L, DeNardo SJ.
    Cancer Res; 1995 Dec 01; 55(23 Suppl):5726s-5728s. PubMed ID: 7493335
    [Abstract] [Full Text] [Related]

  • 13. Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy.
    DeNardo SJ, Burke PA, Leigh BR, O'Donnell RT, Miers LA, Kroger LA, Goodman SL, Matzku S, Jonczyk A, Lamborn KR, DeNardo GL.
    Cancer Biother Radiopharm; 2000 Feb 01; 15(1):71-9. PubMed ID: 10740655
    [Abstract] [Full Text] [Related]

  • 14. Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates.
    Kukis DL, DeNardo SJ, DeNardo GL, O'Donnell RT, Meares CF.
    J Nucl Med; 1998 Dec 01; 39(12):2105-10. PubMed ID: 9867151
    [Abstract] [Full Text] [Related]

  • 15. Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy.
    Kosmas C, Snook D, Gooden CS, Courtenay-Luck NS, McCall MJ, Meares CF, Epenetos AA.
    Cancer Res; 1992 Feb 15; 52(4):904-11. PubMed ID: 1737353
    [Abstract] [Full Text] [Related]

  • 16. Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6.
    O'Donnell RT, DeNardo SJ, Miers LA, Lamborn KR, Kukis DL, DeNardo GL, Meyers FJ.
    Prostate; 2002 Jan 01; 50(1):27-37. PubMed ID: 11757033
    [Abstract] [Full Text] [Related]

  • 17. Intraperitoneal indium-111- and yttrium-90-labeled human IgM (AC6C3-2B12) in nude mice bearing peritoneal carcinomatosis.
    Quadri SM, Malik AB, Chu HB, Freedman RS, Vriesendorp HM.
    J Nucl Med; 1996 Sep 01; 37(9):1545-51. PubMed ID: 8790216
    [Abstract] [Full Text] [Related]

  • 18. Synergistic therapy of breast cancer with Y-90-chimeric L6 and paclitaxel in the xenografted mouse model: development of a clinical protocol.
    Denardo SJ, Richman CM, Kukis DL, Shen S, Lamborn KR, Miers LA, Kroger LA, Perez EA, Denardo GL.
    Anticancer Res; 1998 Sep 01; 18(6A):4011-8. PubMed ID: 9891439
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of a cathepsin-cleavable peptide linked radioimmunoconjugate of a panadenocarcinoma MAb, m170, in mice and patients.
    DeNardo GL, DeNardo SJ.
    Cancer Biother Radiopharm; 2004 Feb 01; 19(1):85-92. PubMed ID: 15068616
    [Abstract] [Full Text] [Related]

  • 20. Comparative biodistribution of indium- and yttrium-labeled B3 monoclonal antibody conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1B4M-DTPA) or 2-(p-SCN-Bz)-1,4,7,10-tetraazacyclododecane tetraacetic acid (2B-DOTA).
    Camera L, Kinuya S, Garmestani K, Brechbiel MW, Wu C, Pai LH, McMurry TJ, Gansow OA, Pastan I, Paik CH.
    Eur J Nucl Med; 1994 Jul 01; 21(7):640-6. PubMed ID: 7957350
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.